Private company

Tesaro

Logo: Tesaro, CC BY-SA 4.0, via Wikimedia Commons5

American pharmaceutical company

Tesaro Inc. is a pharmaceutical company based in Waltham, Massachusetts.3 From Wikipedia, CC BY-SA 4.0

Last updated Oct 19, 2026.

Overview

2010Founded1
  • IndustryPharmaceutical Preparations1
  • HeadquartersWaltham1
  • Websitewww.tesarobio.com
  • Incorporated inDE6
  • Business address1000 Winter Street, Suite 3300, Waltham, Ma 024516
  • Filer categoryLarge accelerated filer6
  • Legal formDomestic Business Corporation4
  • LEI2549002X18IVK5P436794
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered address1000 Winter Street, 02451 Waltham, United States4
  • Registered withCorporations Division (Secretary of the Commonwealth's Office), 2722496874

See how the biggest companies compare on our leaderboards

Tesaro Inc. is a pharmaceutical company based in Waltham, Massachusetts. They focus on drug development for cancer.3

The story

Tesaro was founded in 2010. The company's first commercial product, Varubi, was approved by the FDA in October 2015. As of 2016, the company had 286 full-time employees, 59 of whom had a PhD or MD. The company's product Niraparib was granted priority review and was given a target action date of June 2017 by the FDA. In March 2017, Tesaro won approval for its drug Zejula to treat ovarian cancer. On May 31, 2017, it was reported that Tesaro Inc. was exploring a sale. On December 3, 2018, GSK announced it would acquire the company for $5.1 billion, and the deal was completed on January 22, 2019.

From Wikipedia’s article on Tesaro, shared under CC BY-SA 4.0.7

Leadership

Who has led Tesaro, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Leon O. Moulder Jr.2012–2019
  2. Jack A. Khattar2016

President

  1. Mary Lynne Hedley2013–2019
  2. Jack A. Khattar2016

Chief financial officer

  1. Richard J. Rodgers2012–2013
  2. Timothy R. Pearson2014–2019

Chief operating officer

  1. Mary Lynne Hedley2015–2019
201520202025
Board members and other officers (20)

Products and brands

  • rolapitant

Listed on Wikidata.1

Rolapitant – intravenous form in phase III clinical trials for use in chemotherapy-induced nausea and vomiting

Niraparib – PARP inhibitor in clinical trials for breast and ovarian cancer.

TSR-042

TSR-022

Read the full text

Dostarlimab – In February 2023, the FDA approved dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) for adults with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following a prior platinum-containing regimen in any setting and are not candidates for curative surgery or radiation.

From Wikipedia’s article on Tesaro, shared under CC BY-SA 4.0.7

Timeline

  1. Mar 30, 2016New chief executive Jack A. Khattar becomes CEO8
  2. Jun 27, 2012New chief executive Leon O. Moulder Jr. becomes CEO9
  3. 2010Founded Founded1

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30